Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16161051 | 1.00 | CDK4 (0.32) | CDK4FLT3 | |
| Hydrochloric Acid SCHEMBL2910420 | 0.99 | CDK4 (0.32) | CDK4FLT3 | |
| Hydrochloric Acid SCHEMBL2907767 | 0.99 | CDK4 (0.32) | CDK4FLT3 | |
| Hydrochloric Acid SCHEMBL2907769 | 0.99 | CDK4 (0.32) | CDK4FLT3 | |
| SCHEMBL13090273 | 0.78 | JAK3 (0.36) | CDK4FLT3 | |
| Hydrochloric Acid SCHEMBL2904368 | 0.77 | JAK3 (0.36) | CDK4FLT3 | |
| SCHEMBL2110174 | 0.77 | — | — | |
| SCHEMBL10200672 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL2909517 | 0.75 | HTR2A (0.34) | CDK4FLT3 | |
| SCHEMBL13090288 | 0.72 | HTR2A (0.35) | CDK4FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2216023-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-08-11 | — | — | EP | claimed |
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216023-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | HTR2C, HTR5A, HTR3C | CDK4 1018/4885FLT3 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.